Potential Clinical and Economic Value of Long-Acting Preexposure Prophylaxis for South African Women at High-Risk for HIV Infection by Walensky, Rochelle P. et al.
Potential Clinical and Economic
Value of Long-Acting Preexposure
Prophylaxis for South African
Women at High-Risk for HIV Infection
The Harvard community has made this
article openly available.  Please share  how
this access benefits you. Your story matters
Citation Walensky, Rochelle P., Margo M. Jacobsen, Linda-Gail Bekker,
Robert A. Parker, Robin Wood, Stephen C. Resch, N. Kaye Horstman,
Kenneth A. Freedberg, and A. David Paltiel. 2015. “Potential Clinical
and Economic Value of Long-Acting Preexposure Prophylaxis for
South African Women at High-Risk for HIV Infection.” The Journal
of Infectious Diseases 213 (10): 1523-1531. doi:10.1093/infdis/jiv523.
http://dx.doi.org/10.1093/infdis/jiv523.
Published Version doi:10.1093/infdis/jiv523
Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:26860302
Terms of Use This article was downloaded from Harvard University’s DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at http://
nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAA
The Journal of Infectious Diseases
M A J O R A R T I C L E
Potential Clinical and Economic Value of Long-Acting
Preexposure Prophylaxis for South African Women at
High-Risk for HIV Infection
Rochelle P. Walensky,1,2,3,5,6 Margo M. Jacobsen,1,3 Linda-Gail Bekker,11 Robert A. Parker,1,3,4,6 Robin Wood,11 Stephen C. Resch,7 N. Kaye Horstman,1,3
Kenneth A. Freedberg,1,2,3,6,8,9 and A. David Paltiel10
1Medical Practice Evaluation Center, 2Division of Infectious Disease, 3Division of General Internal Medicine, and 4MGH Biostatistics Center, Massachusetts General Hospital, 5Division of Infectious
Disease, Brigham and Women’s Hospital, and 6Harvard University Center for AIDS Research, Harvard Medical School, 7Center for Health Decision Science, and 8Department of Health Policy and
Management, Harvard T. H. Chan School of Public Health, and 9Department of Epidemiology, Boston University School of Public Health, Massachusetts; 10Yale School of Public Health, New Haven,
Connecticut; and 11Desmond Tutu HIV Centre, Institute of Infectious Disease and Molecular Medicine, Faculty of Medicine, University of Cape Town, South Africa
(See the editorial commentary by Landovitz and Grinsztejn on pages 1519–20.)
Background. For young South African women at risk for human immunodeﬁciency virus (HIV) infection, preexposure prophy-
laxis (PrEP) is one of the few effective prevention options available. Long-acting injectable PrEP, which is in development, may be
associated with greater adherence, compared with that for existing standard oral PrEP formulations, but its likely clinical beneﬁts and
additional costs are unknown.
Methods. Using a computer simulation, we compared the following 3 PrEP strategies: no PrEP, standard PrEP (effectiveness,
62%; cost per patient, $150/year), and long-acting PrEP (effectiveness, 75%; cost per patient, $220/year) in South African women at
high risk for HIV infection (incidence of HIV infection, 5%/year). We examined the sensitivity of the strategies to changes in key
input parameters among several outcome measures, including deaths averted and program cost over a 5-year period; lifetime HIV
infection risk, survival rate, and program cost and cost-effectiveness; and budget impact.
Results. Compared with no PrEP, standard PrEP and long-acting PrEP cost $580 and $870 more per woman, respectively, and
averted 15 and 16 deaths per 1000 women at high risk for infection, respectively, over 5 years. Measured on a lifetime basis, both
standard PrEP and long-acting PrEP were cost saving, compared with no PrEP. Compared with standard PrEP, long-acting PrEP was
very cost-effective ($150/life-year saved) except under the most pessimistic assumptions. Over 5 years, long-acting PrEP cost $1.6
billion when provided to 50% of eligible women.
Conclusions. Currently available standard PrEP is a cost-saving intervention whose delivery should be expanded and optimized.
Long-acting PrEP will likely be a very cost-effective improvement over standard PrEP but may require novel ﬁnancing mechanisms
that bring short-term ﬁscal planning efforts into closer alignment with longer-term societal objectives.
Keywords. HIV; preexposure prophylaxis; cost-effectiveness; South Africa; long-acting agents.
Human immunodeﬁciency virus (HIV) infection continues to
be a major cause of mortality in sub-Saharan Africa [1]. Despite
growth in antiretroviral therapy (ART) coverage, the incidence
of HIV infection among South African female teenagers contin-
ues to grow, with the prevalence of infection increasing from
2.4% to 17.4% between ages 14 and 24 years [2]. Preexposure
prophylaxis (PrEP) has proven effective at preventing HIV in-
fection [3, 4] and is being considered for low-income and
middle-income countries where the incidence of infection is
high [5, 6]. However, the success of current standard oral
PrEP (Std-PrEP) hinges on daily adherence, with overall effec-
tiveness of Std-PrEP in trials ranging from 0% to 94% [3, 4, 7–
12]. Novel long-acting formulas of PrEP (LA-PrEP) provide
sustained drug levels when administered bimonthly or quarterly
and could help improve adherence [13, 14]. These formulations
would, however, require a brief (approximately 1-month) peri-
od of short-term adherence, to rule out acute toxicity with a
short-acting formulation, prior to long-acting dosing. Phase II
clinical trials (the HIV Prevention Trials Network [HPTN] 077
study, the Centre for the AIDS Programme of Research in South
Africa [CAPRISA] 014 study, the ÉCLAIR study, and the
HPTN 076 study) are planned or ongoing for 2 LA-PrEP for-
mulas, cabotegravir/GSK1265744 and rilpivirine/TMC278LA
[15–17]. In animal studies, prophylaxis efﬁcacies of rectal and
vaginal formulations of these agents have reached 75%–100%
[14, 18, 19].
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Although modeling studies have already projected the cost-
effectiveness and substantial clinical beneﬁts of properly used
Std-PrEP, the comparative cost and effectiveness of alternative
PrEP formulations are unknown [20–23]. Our objective was to
anticipate the development of newer PrEP formulations, to in-
vestigate effectiveness thresholds that would justify the addi-
tional cost over existing PrEP alternatives in a population of
high-risk young women in South Africa, and to identify the
key drivers and uncertainties behind that assessment.
METHODS
Analytic Overview
Weused the Cost-Effectiveness of Preventing AIDSComplications–
International (CEPAC-I) model to project clinical beneﬁts,
estimate upfront investments, and establish cost-effectiveness
performance benchmarks for LA-PrEP for high-risk South
African women aged 18–25 years. Leveraging our prior work
on Std-PrEP [22, 23], we examine 3 strategies: (1) no PrEP,
(2) Std-PrEP with 62% effectiveness [10], and (3) LA-PrEP
with 75% effectiveness [14, 18, 24]. We examined the sensitivity
of our ﬁndings to uncertainty in LA-PrEP effectiveness, HIV in-
fection incidence, duration of PrEP use, and LA-PrEP program-
matic cost. Model outcomes included lifetime risk of HIV
infection (per 1000 women at high risk), 5-year mortality and
cost, cost per infection averted, lifetime survival and cost, and in-
cremental cost-effectiveness ratios (ICERs) in 2014 US dollars
per life-year saved. All outcomes used for economic evaluation
are reported using a 3% annual discount rate. We labeled pro-
grams as “very cost-effective” if their ICERs were less than the
South African annual per capita gross domestic product (GDP;
ie, $7000) and as “cost-effective” if their ICERs were <3 times
the GDP [25,26].We also examined the 1-year and 5-year budget
impacts of an LA-PrEP strategy in this population.We conducted
our analysis from the HIV program perspective and excluded
later medical care costs for HIV-uninfected women.
Model Overview
CEPAC-I is a state-transitionsimulationofHIVprevention, casede-
tection, and disease progression that is used to project clinical, epi-
demiologic, and economic outcomes of HIV prophylaxis and
treatment programs. Model users deﬁne cohort characteristics,
HIVscreeningpolicies, treatmentregimens,anddisease-monitoring
policies, which all inﬂuence the natural history of HIV disease pro-
gression. For this analysis, all model entrants were PrEP-eligible,
HIV-uninfected, high-risk South African women.
PrEP Module
HIV-negative women (mean age, 18 years) entered the module
and were subjected to an age-dependent incidence of HIV infec-
tion. To simulate HIV screening that might occur in communities,
all women underwent HIV testing every 3 years, on average [6].
We assumed that PrEP effectiveness, measured as a percent-
age reduction in HIV infection incidence, incorporated both
intrinsic drug efﬁcacy and anticipated client adherence.
Women receiving one of the PrEP strategies underwent quarter-
ly HIV screening to ensure that antiretroviral agents were not
being prescribed suboptimally as prophylaxis to HIV-infected
women [27]. In the base case, we assumed that women only re-
ceived PrEP when their HIV infection risk was highest (ie, from
the age at model entry through age 25 years) and relaxed this
assumption in sensitivity analyses.
Disease Module
Women who became infected with HIV entered the disease mod-
ule and traversed the natural history of HIV progression until they
received a diagnosis of HIV infection via ongoing HIV screening
efforts or via PrEP-associated HIV testing or until they developed
a severe opportunistic infection [23].Once HIV infection was de-
tected, PrEP was discontinued, and the woman became eligible
for guideline-concordant HIV care [28, 29], including ART initi-
ation at a CD4+ T-cell count of < 500 cells/µL. In the model, ART
suppressed viral load, increased the CD4+ T-cell count, and de-
creased the risk of opportunistic infections and death [29, 30].
Per South African standards, we assumed 2 sequential lines of
ART: ﬁrst-line efavirenz-based therapy and second-line protease
inhibitor–based therapy. For women receiving PrEP who became
infected with HIV, we assumed in the base case that there was no
resistance-related reduction in the efﬁcacy of ﬁrst-line ART, be-
cause LA-PrEP uses different antiretroviral agents than those
used for treatment in South Africa [28]. We then conducted sen-
sitivity analyses around this assumption, implementing a 10%
absolute decrease in the rate of virologic suppression during
ﬁrst-line ART for those who were infected.
Model Input Data
Demographic Parameters
We simulated a cohort of 1 million high-risk South African
women with a mean age (±SD) of 18 ± 2 years and an annual
incidence of HIV infection of 5.0% until age 26 years, as report-
ed in the Preexposure Prophylaxis Trial for HIV Prevention
Among African Women (FEM-PrEP; 5.0%) [11], the Vaginal
and Oral Interventions to Control the Epidemic (VOICE)
study (5.7%) [9], and the 2012 South African National Preva-
lence, Incidence, and Behaviour Survey (SANPIBS; 4.5%) [2].
At age ≥26 years, the annual incidence of HIV infection was
age adjusted to that for the average female in South Africa (ie,
2.1% for women aged 26–44 years and 0.85% for women aged
≥45 years), as derived from the SANPIBS and the 2011 South
African census (Table 1) [2, 31].
PrEP Effectiveness
Animal studies of LA-PrEP demonstrated prevention efﬁcacies
ranging from 75% to 100% (Table 1) [14, 18, 24]. We used an
LA-PrEP effectiveness of 75% in the base case, to approximate
1 missed LA-PrEP dose per year. Trial-based effectiveness esti-
mates for Std-PrEP have varied from 0% (in the FEM-PrEP and
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VOICE study) in nonadherent populations to 94% (in the Part-
ners PrEP study) in fully adherent populations [4, 9, 11, 12].
Acknowledging this wide range, we set a relatively high effec-
tiveness estimate of 62% (from the TDF2 study [10]) for Std-
PrEP in the base case (the effectiveness among heterosexual
women ranges from 49% to 75%). We intentionally used 62%
instead of a lower reported effectiveness because this sets a rea-
sonable yet high standard against which we could compare the
value of LA-PrEP (data in Supplementary Figure 4 compare
LA-PrEP to Std-PrEP with 49% effectiveness). We chose the
TDF2 study speciﬁcally because it was conducted with a target
study population similar to that used in our analysis. PrEP tox-
icity was excluded from the base case because the majority of
PrEP trials have reported no difference in the rate of serious
adverse events across study groups [3, 4, 7, 9, 10] and because
a study on the safety and tolerability of LA-PrEP reported no
severe adverse events [32].
PrEP Costs
We estimated the monthly drug cost of Std-PrEP (tenofovir-
emtricitabine) as $6.25 [33]. Although the cost of LA-PrEP is
unknown, pricing of long-acting versus short-acting contracep-
tives showed that long-acting injectables cost nearly the same as
or less than daily pills [34]. However, we conservatively approx-
imated the LA-PrEP drug cost to be double that of Std-PrEP (ie,
$12.50 monthly). The programmatic cost of both LA-PrEP and
Std-PrEP incorporated the cost of drug, biannual chemistry
panels, and clinic visits. Each biannual chemistry panel costs
$15.50 [35], and a quarterly routine clinic visit costs $10.40.
Thus, in our model the base case total monthly programmatic
Table 1. Selected Model Input Values
Variable Base Case Value Range in Sensitivity Analysis Reference
Baseline cohort characteristic
Age, y, mean ± SD 18 ± 2 . . . Assumption
Female sex, % 100 . . . Assumption
Annual HIV infection incidence, by age, %
≤25 y 5.0 2.5–9.0 [2, 9, 11]
26–44 y 2.1 1.0–4.0 [2, 31]
≥45 y 0.85 . . . [2, 31]
PrEP characteristic
Long-acting PrEP effectiveness, % 75 0–100 [14, 18, 24]
Standard PrEP effectiveness, % 62 39–62 [8, 10]
HIV test characteristic
Testing frequency during PrEP receipt Every 3 mo 1, 6, and 12 mo [27]
Background testing frequency without PrEP receipt Every 3 y 1, 5, 7, and 10 y Assumption
Clinical characteristic after HIV infection
Initial CD4+ T-cell count, cells/µL, mean ± SD 559 ± 236 . . . [36–38]
ART efficacy of first- and second-line therapies
Patients with viral suppression at 48 wk, % 92 50–100 [29]
Rate of failure after 48 wk, per 100 person-years 1.4 . . . [29]
Increase in CD4+ T-cell count at 48 wk, cells/µL, mean 206 . . . [29]
Cost, 2014 $
Discount rate, % 3 0–5 Assumption
PrEP program cost
Std-PrEP drug (TDF/FTC), monthly (annually) 6.25 (75) . . . [33]
LA-PrEP drug, monthly (annually) 12.50 (150) . . . Assumption
Chemistry panel, per test (annually) 15.50 (31) . . . [35]
HIV test, per test (annually) 1.20 (5) 0.50–3.00 [35]
Clinic visit, per visit (annually) 10.40 (42) . . . [40]
Total Std-PrEP program cost, monthly 12.30 . . .
Total LA-PrEP program cost, monthly 18.60 1.90–37.10
Antiretroviral therapy (annually)
First line: TDF/FTC/EFV or TDF/3TC/EFV 192 100–300 [39]
Second line: AZT/3TC+LPV/r 412 200–600 [39]
HIV load testing, cost per test 36 15–55 [35]
CD4+ T-cell count testing, cost per test 7 3–11 [35]
Routine care cost, monthly (ranges by CD4+ T-cell count) 20–157 . . . [35, 41]
Abbreviations: 3TC, lamivudine; ART, antiretroviral therapy; AZT, zidovudine; EFV, efavirenz; FTC, emtricitabine; HIV, human immunodeficiency virus; LA-PrEP, long-acting preexposure
prophylaxis; LPV/r, lopinavir/ritonavir; PrEP, preexposure prophylaxis; SD, standard deviation; Std-PrEP, standard preexposure prophylaxis; TDF, tenofovir.
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cost for patients receiving Std-PrEP was $12.30 and that for LA-
PrEP was $18.60. We conducted sensitivity analyses examining
variations in overall programmatic cost, noting that, for LA-
PrEP, only 70% of the overall cost was related to the cost of
the drug itself (Table 1).
Other Inputs
Other key inputs are provided in Table 1 [2, 8–11, 14, 18, 24, 27,
29, 31, 33, 35–41].
Sensitivity Analyses
In sensitivity analyses, we varied LA-PrEP effectiveness, HIV
infection incidence, age at PrEP discontinuation, and LA-
PrEP programmatic cost. We then chose extreme values within
realistic ranges of key PrEP-related parameters and combined
them to create plausibly optimistic and pessimistic scenarios
for LA-PrEP, compared with no PrEP and Std-PrEP.
Budget Impact
To inform ﬁnancial planning, we conducted 1-year and 5-year
budget impact assessments of alternative PrEP strategies. We
adopted the perspective of the South African HIV prevention
program, restricting our attention to undiscounted PrEP pro-
gram cost (including drug, clinic visit, and chemistry panel
cost) and assumed a 50% uptake. We estimated the number
of PrEP-eligible South African women aged 18–25 years [31]
by deducting the percentage of women with prevalent HIV in-
fection (range, 2.4%–28.4%) from age-stratiﬁed population esti-
mates [2]. Beyond the ﬁrst year, we introduced women aged 18
years who were newly eligible for PrEP and removed the expect-
ed number of women with incident cases, given Std-PrEP or
LA-PrEP effectiveness. We then multiplied this ﬁgure by the an-
nual Std-PrEP or LA-PrEP program cost and subtracted the an-
nual ART-associated cost savings resulting from PrEP-averted
infections.
RESULTS
Base Case
Clinical Outcomes
The lifetime risk of HIV infection in high-risk South African
women with no PrEP was 630 cases/1000. With an average of
8 years of PrEP use, the risk of infection declined, ranging
from 540 cases/1000 with Std-PrEP (effectiveness, 62%) to
510 cases/1000 with LA-PrEP (effectiveness, 75%). The undis-
counted per-person life expectancy starting from model entry
(mean age, 18 years)—including women with and those without
HIV infection—was shortest with the no PrEP strategy (47.7
years). Life expectancy for the PrEP strategies extended from
50.1 years (for Std-PrEP) to 50.4 years (for LA-PrEP). As a
point of validation, this range of life expectancy was consistent
with reports for South African HIV-infected adults receiving
ART [42, 43]. PrEP also averted HIV-related deaths: over a 5-
year period, LA-PrEP averted 16 HIV-related deaths per 1000
high-risk women, compared with no PrEP (Table 2).
Cost and Cost-effectiveness Outcomes
Over a 5-year horizon, the per-person costs of PrEP were sub-
stantially higher ($840 for Std-PrEP and $1130 for LA-PrEP)
than for no PrEP ($260). The cost of averting 1 HIV infection
over a lifetime was estimated as $10 100 for Std-PrEP and
$12 400 for LA-PrEP. When all 3 strategies were compared
over a lifetime, including the cost of ART, the Std-PrEP strategy
was the least expensive ($5270). Compared with no PrEP, both
Std-PrEP and LA-PrEP were less expensive and more effective,
and therefore cost saving. Compared with Std-PrEP, the ICER
of LA-PrEP was $150/life-year saved (Table 2).
The 3 strategies differed in terms of the components of their
costs. Increasingly aggressive PrEP approaches required a great-
er investment in PrEP-related program cost (Figure 1). Howev-
er, these investments were offset by savings in HIV-related cost
(Figure 1). Compared with no PrEP, spending an average of
$1530 per person on LA-PrEP resulted in $1960 less spent
per person on total HIV care.
Table 2. Base Case Results
Variable
No
PrEP
Std-PrEP
(62%, $12.30/mo)
LA-PrEP
(75%, $18.60/mo)
Lifetime HIV infection
risk,a cases/1000
high-risk women
630 540 510
Undiscounted per-
person life
expectancy,b y
47.7 50.1 50.4
5-y HIV infections
averted, compared
with no PrEP, no./
1000 high-risk
women
. . . 127 156
5-y HIV-related deaths
averted, compared
with no PrEP, no./
1000 high-risk
women
. . . 15 16
Discounted 5-y cost per
high-risk woman,c $
260 840 1130
Discounted PrEP cost
per lifetime HIV
infection averted, $
. . . 10 100 12 400
Discounted life
expectancy, y
23.9 24.8 25.0
Discounted per person
lifetime cost,c $
5730 5270 5300
ICER vs no PrEP, $/life-
year saved
. . . Cost savingd Cost savingd
ICER vs Std-PrEP, $/life-
year saved
NA . . . 150
Abbreviations: HIV, human immunodeficiency virus; ICER, incremental cost-effectiveness
ratio; LA-PrEP, long-acting preexposure prophylaxis; NA, not applicable; PrEP, preexposure
prophylaxis; Std-PrEP, standard preexposure prophylaxis.
a Lifetime HIV infection risk was projected from the cohort starting age of 18 years.
b Per-person life expectancy was projected from the cohort starting age of 18 years. A per-
person undiscounted life expectancy of 50 years corresponds here to an overall life
expectancy of 68 years.
c Costs were measured in 2014 $ and discounted at a rate of 3%.
d PrEP was more effective and less expensive than the comparator strategy.
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Strategies also differed in terms of their cost and beneﬁt tra-
jectories over time. When we focused on the ﬁrst 5 years after
program implementation, increasingly aggressive PrEP strate-
gies were costlier (Table 2). Viewed over a longer horizon, how-
ever, PrEP interventions were less costly. The LA-PrEP strategy
required a higher initial investment (Figure 2A); its discounted
cost greatly exceeded that of the no PrEP strategy and slightly
exceeded that of the Std-PrEP strategy over the ﬁrst 5–15
years. However, the higher eventual cost related to increased
numbers of HIV infections and treatment with the no PrEP
strategy caused the cumulative discounted cost curves to con-
verge (the curves crossed at approximately year 29; data not
shown). Beyond that point, the LA-PrEP strategy had lower cu-
mulative cost. LA-PrEP also reduced the number and delayed
the occurrence of HIV-related deaths (Figure 2A) and the num-
ber of women requiring ART (Figure 2B).
Sensitivity Analyses
We summarize our extensive sensitivity analyses in the section
below, reporting on key instances variation in the input data as-
sumptions had a material impact on our policy ﬁndings or were
clinically important. A fuller report is provided in the Supple-
mentary Materials.
LA-PrEP Effectiveness
Clinical beneﬁts increased with increases in LA-PrEP effective-
ness (Table 3). Lifetime risk of HIV infection decreased from
510 cases/1000 high-risk women (base case effectiveness, 75%)
to 490 and 470 cases/1000 high-risk women (effectiveness, 85%
and 95%, respectively); similarly, more HIV-related deaths were
averted as effectiveness increased. Average lifetime cost also de-
creased, dropping as low as $4530 per woman at 95% effective-
ness; as total lifetime cost decreased, PrEP accounted for a greater
proportion of total cost.
HIV Infection Incidence
When annual incidence was reduced from 5.0% to 2.5% (the
population average risk in South Africa), LA-PrEP no longer
achieved cost savings, and the PrEP cost per averted infection
increased to $21 800; however, LA-PrEP was very cost-effective
as compared to no PrEP, with an ICER of $680/life-year saved
(<10% annual per capita GDP). Among very high-risk women—
similar to those observed in the CAPRISA 004 study (HIV infec-
tion incidence, 9.0%/year) [8]—LA-PrEP averted 27 deaths/1000
women over 5 years and cost $8200 per averted infection. Supple-
mentary Figures 3 and 4 provide 2-way sensitivity analyses of
LA-PrEP as compared to Std-PrEP at alternative Std-PrEP
efﬁcacies (62% and 49%) and in average-risk, high-risk, and
very high-risk populations.
Duration of LA-PrEP Use
In the base case analysis, we assumed that LA-PrEP was admin-
istered from model entry (ie, at a mean age of 18 years) through
age 25 years. If LA-PrEP was administered for longer durations
—through age 35 or 45 years—a greater cumulative per-person
investment (from $5300 to $5840 or $6240) would be required,
LA-PrEP program cost would account for a larger fraction
of total outlay (48%–60%), and lifetime risk of HIV would
Figure 1. Average discounted per-person lifetime cost distribution of the no preexposure prophylaxis (PrEP), standard PrEP (Std-PrEP), and long-acting PrEP (LA-PrEP) strat-
egies. Discounted per-person lifetime costs (in 2014 $) are provided on the vertical axis. Costs associated with PrEP administration (drug costs, safety labs, and clinic visits) are
shown in dark purple. Costs associated with human immunodeficiency virus (HIV) care are blue. Antiretroviral therapy (ART) costs are lightest blue. HIV routine care costs, such
as clinic visits, are dark blue. Costs associated with laboratory monitoring and AIDS-defining events for HIV-infected people are medium blue. Total costs (sum of overall PrEP
costs and overall HIV costs), as well as lifetime risk of HIV infection associated with each strategy, are in the rows below the figure. These values demonstrate the interaction
between the PrEP investment and its prevention impact. Investments in PrEP programs resulted in lower HIV-related costs and substantially fewer HIV infections.
Abbreviation: OI, opportunistic infection.
Value of Long-Acting PrEP in South Africa • JID 2016:213 (15 May) • 1527
decrease from 510 to 430 or 340 cases per 1000 high-risk
women (Supplementary Figure 1). Alternatively, if PrEP “fa-
tigue” resulted in its use only through age 19 years, lifetime
cost for LA-PrEP would be higher than in the base case, despite
reduced PrEP expenditure, because 2 years of PrEP use would
not avert enough infections to decrease lifetime cost substan-
tially as compared to the no PrEP strategy.
LA-PrEP Cost
When the overall LA-PrEP program cost decreased by 50% of
the base case value to $9/month, cost savings were achieved
as early as 13 years after program implementation, per-person
lifetime cost was $4540, and the PrEP cost per infection averted
was $6200. If LA-PrEP overall program cost was 150% of the
base case ($28/month)—as might occur if the dosing frequency
were every 2 months—the ICER for LA-PrEP as compared to
no PrEP was very cost-effective, at $280/life-year saved (4% of
GDP), and was cost-effective as compared to Std-PrEP, at
$7870/life-year saved (112% of GDP; Supplementary Figures 2
and 3); at 150% of cost, LA-PrEP cost $18 400 per infection
averted. At a monthly cost exceeding $45 and $310, LA-PrEP
ceased to be cost-effective as compared to Std-PrEP and no
PrEP, respectively.
Resistance-Related Reduction in ART Efﬁcacy
A sensitivity analysis adding a 10% absolute reduction in viro-
logic suppression due to resistance among persons who experi-
ence breakthrough HIV infections during LA-PrEP produced
no material impact on any major outcome or on the resultant
policy recommendation.
Optimistic and Pessimistic LA-PrEP Scenarios
In a best-case scenario for LA-PrEP use, highly effective LA-
PrEP (effectiveness, 85%) was administered at low cost ($9
monthly) and successfully targeted to very high-risk (annual in-
cidence, 9%) women. Use of LA-PrEP in this optimistic scenar-
io (Table 3), averted 29 deaths/1000 women in the ﬁrst 5 years,
cost $4620 per woman over her lifetime, and cost $3600 per in-
fection averted as compared to no PrEP. In a pessimistic scenar-
io, less effective LA-PrEP (effectiveness, 65%) was administered
at higher cost ($28 monthly) to the general population of
women with average risk of HIV infection (annual incidence,
2.5%). Even under this pessimistic scenario, LA-PrEP had an
ICER of $2420/life-year saved as compared to no PrEP (very
cost-effective, 35% of GDP) but it was not cost-effective as com-
pared to Std-PrEP ($165 360/life-year saved). LA-PrEP reduced
the lifetime risk of HIV infection to 500 cases/1000 high-risk
women and cost $37 500 per infection averted, compared
with no PrEP.
Budget Impact Analysis
An estimated 3 million South African women ages 18–25 years
are eligible for PrEP each year [31]. Providing LA-PrEP to half
this population, at an average per-person programmatic cost of
$220 annually, would cost $327 million in the ﬁrst year (Std-
PrEP cost, $217 million) and $1.6 billion over 5 years (Std-
PrEP cost, $1.1 billion).
DISCUSSION
New long-acting antiretroviral formulations may soon provide a
PrEP option that does not require daily adherence to pills. An-
ticipating the development of long-acting options, we compared
Figure 2. Cumulative discounted costs, human immunodeficiency virus (HIV)–
related deaths, and women receiving antiretroviral therapy (ART) for the no preexpo-
sure prophylaxis (PrEP), standard PrEP (Std-PrEP), and long-acting PrEP (LA-PrEP)
strategies. A, The cumulative discounted cost per high-risk woman is shown on
the left vertical axis, and the cumulative number of HIV-related deaths is on the
right vertical axis. Lines correspond to the per-person cumulative cost on the left
axis: the red line is the no PrEP strategy, the orange line is the Std-PrEP strategy,
and the blue line is the LA-PrEP strategy. The changes in the slopes of the blue and
orange lines occurring around year 8 correspond to the time at which PrEP was
stopped and required investments therefore decreased. Costs of the LA-PrEP strategy
(blue line) and the no PrEP strategy (red line) converge over time and ultimately cross
at year 29 (data not shown). The pink shaded area corresponds to the number of HIV-
related deaths that occurred with no PrEP (109 000 deaths by year 25). The orange
shaded area corresponds to the number of HIV-related deaths that occurred with Std-
PrEP (63 000 deaths by year 25). The blue shaded area corresponds to the number of
HIV-infected deaths that occurred with an LA-PrEP program (58 000 deaths by year
25). B, The cumulative number of women who received ART is shown on the left
vertical axis. The red area corresponds to the number of women in the no PrEP
group who received ART (363 000 women were receiving ART by year 25). The or-
ange area corresponds to the number in the Std-PrEP group who received ART
(279 000 women were receiving ART by year 25). The blue area corresponds to
the number of women in the LA-PrEP group who were receiving ART (252 000
women were receiving ART by year 25).
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the potential clinical beneﬁts, additional cost, cost-effectiveness,
and budget impact of existing and novel PrEP strategies. We
found that, in high-risk populations (annual HIV infection in-
cidence, 5.0% [9, 11]), currently available oral PrEP formula-
tions, with an effectiveness of 62%, would avert deaths, extend
life expectancy, reduce the lifetime risk of HIV infection, and
save money in the long term, compared with no PrEP. LA-
PrEP, with an effectiveness of 75%, could avert even more
deaths, provide longer life expectancy, and result in an even
lower lifetime risk of HIV infection. LA-PrEP would also be
cost saving as compared to no PrEP in the long term. Compared
with standard PrEP, it would have an attractive ICER ($150/life-
year saved)—just 2% of South Africa’s GDP per capita. This is
substantially less than reported cost-effectiveness ratios for ART
in South Africa, ranging from $1240 to $2400/life-year saved
(updated to 2014 US dollars) [29, 41, 44, 45].
Viewed on an individual basis, LA-PrEP would cost about
$12 400 (discounted) per infection averted, more than twice
the per-person lifetime discounted cost of care in the absence
of PrEP ($5730). However, the upfront investment in LA-
PrEP would be offset in the long term by reduced HIV trans-
mission and a lower overall cost of HIV treatment.
Despite long-term cost savings, the scale-up of a PrEP pro-
gram, even if successfully targeted, would be substantial. Ac-
cording to the South African National Strategic Plan, $2.8
billion is needed in the 2015–2016 ﬁscal year to meet the
goals for prevention and treatment of sexually transmitted dis-
eases, tuberculosis, and HIV infection, a value that already
Table 3. Sensitivity Analysis Results
LA-PrEP Strategy
Lifetime Risk of HIV
Infection,a Infections/
1000 High-Risk
Women
5-y Averted HIV-
Related Deaths, No./
1000 High-risk
Womenb
Discounted Per-
Person Lifetime
Cost,c $
PrEP Cost,
% of Total
Cost
Discounted PrEP Cost
per Lifetime HIV
Infection Averted,c $
ICER, $/Life-Year Saved
Versus
No PrEP
Versus
Std-PrEP
Versus No
PrEP
Versus
Std-PrEP
Base cased 510 16 1 5300 28 12 400 Cost
savinge
150
Effectiveness, %
65 530 15 0 5660 26 14 200 Cost
saving
18 560
85 490 17 2 4920 31 10 800 Cost
saving
Cost
saving
95 470 18 3 4530 34 9600 Cost
saving
Cost
saving
HIV infection annual incidence until age 25 y, %
2.5 490 8 0 4830 32 21 800 680 4790
9.0 550 27 2 6000 24 8200 Cost
saving
Cost
saving
PrEP through age
19 y 600 8 0 5640 8 15 800 Cost
saving
590
35 y 430 16 1 5840 48 14 100 60 1770
45 y 340 16 1 6240 60 13 000 280 2 490
Program cost, % of basecase
50 ($9/mo) 510 16 1 4540 16 6200 Cost
saving
Cost
saving
150 ($28/mo) 510 16 1 6040 37 18 400 280 7870
Scenario
Optimistic (85%
efficacy, 50%
cost, 9.0%
incidence)
520 29 4 4620 16 3600 Cost
saving
Cost
saving
Pessimistic (65%
efficacy, 150%
cost, 2.5%
incidence)
500 8 0 5780 39 37 500 2420 165 360
Abbreviations: HIV, human immunodeficiency virus; ICER, incremental cost-effectiveness ratio; LA-PrEP, long-acting preexposure prophylaxis; PrEP, preexposure prophylaxis; Std-PrEP,
standard preexposure prophylaxis.
a Lifetime HIV infection risk was projected from the cohort starting mean age of 18 years.
b Averted deaths were rounded down to the nearest integer.
c Costs were measured in 2014 $.
d The base case used LA-PrEP with an effectiveness of 75% in a population of women with 5.0% annual HIV infection incidence at a monthly cost of $18.60. PrEP was provided through age 25 y.
e PrEP was more effective and less expensive than the comparator strategy.
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results in a $460 million gap in available funding [46]. Approx-
imately 20% ($560 million) is earmarked for HIV prevention
and testing initiatives, likely primarily targeted to the 28 million
individuals aged 10–40 years. Yet, our estimated annual budget
for LA-PrEP, assuming 50% uptake in high-risk women aged
18–25 years, is $327 million for just 1.5 million women.
Thus, for LA-PrEP to truly be sustainable and scalable, creative
ﬁscal strategies will be required. Concessionary loans, which
would spread the cost of a PrEP program over a long period,
might be one avenue of ﬁnancing [47].
Our study has several limitations. First, while the efﬁcacy of
oral PrEP has been well established in clinical trials, its effec-
tiveness in real-world medical practice has not. Further, the
effectiveness and cost of LA-PrEP are unknown. We conduct-
ed broad sensitivity analyses around potential target popula-
tions and LA-PrEP prophylactic efﬁcacy and cost values, but
the point estimates will remain uncertain until more data are
available. We did not include the impact of potential fatigue
associated with injectables or loss to follow up in the LA-PrEP
(or Std-PrEP) program, as has been associated with long-
acting contraceptives [48]. However, we examined shorter
LA-PrEP horizons (through age 19 years); we believe that
LA-PrEP, compared with Std-PrEP, would be less likely asso-
ciated with disengagement, because LA-PrEP would require
much less intensive maintenance and follow-up care. Never-
theless, the LA-PrEP safety proﬁle has yet to be established.
The prolonged pharmacokinetic tail of long-acting nanofor-
mulations bears careful monitoring for toxicities (eg, fulmi-
nant drug-related liver or cutaneous drug reactions) and
their potential contribution to the need for discontinuation
and for medical care.
We also accounted only for ﬁrst-generation, age-dependent
transmission to HIV-negative women; inclusion of later-
generation infections, especially in young women, would serve
to make LA-PrEP even more cost-effective, with negligible im-
pact on the early required budget. Further, we restricted our at-
tention to women >18 years in this analysis. Expanding our
assessment to include sexually active adolescent girls—a
group with a similarly high HIV infection incidence—would
likely both strengthen our cost-effectiveness ﬁndings and
heighten the budget impact concerns regarding LA-PrEP.
Taken as a whole, our ﬁndings suggest a 2-part policy re-
sponse. First, the delivery of existing oral PrEP formulations,
which are very cost-effective, should be expanded and opti-
mized for young, high-risk South African women. Scale-up of
PrEP should be accompanied by improved community educa-
tion and adherence interventions to ensure its effectiveness in
the population. Data from large cohorts of women still report
annual HIV infection incidences as strikingly high as 9.0%.
An immediate need for effective prevention will persist until
the full scale-up of treatment to all ART-eligible persons can
be achieved [49, 50]. For young women at high risk for HIV
infection, oral PrEP is one of the very few effective and cost-
saving HIV prevention alternatives available.
Second, the research and development effort should be ex-
panded to bring a viable LA-PrEP formulation to market. The
evidence currently at our disposal suggests that long-acting
PrEP could be a very cost-effective alternative to standard for-
mulations. Depending on cost, discontinuation rates, and toxic-
ities that are as-yet unanticipated, it might offer a small but still
acceptable improvement (as injectable contraception is to oral
contraceptive pills). However, even under the most optimistic
scenario, a long-acting PrEP formulation is still several years
away from implementation; moreover, a long-acting PrEP for-
mulation will place an even greater strain on existing HIV pre-
vention budgets. For this reason, the research effort to conﬁrm
the clinical effectiveness of newer LA-PrEP formulations must
go hand in hand with a development effort to identify novel ﬁ-
nancing mechanisms that bring short-term ﬁscal planning ef-
forts into closer alignment with longer-term societal objectives.
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